Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Gac Med Mex ; 133(4): 355-9, 1997.
Article in Spanish | MEDLINE | ID: mdl-9410796

ABSTRACT

We describe the case of a patient with myelodysplastic syndrome (MDS) classified as Refractory Anemia with our Excess blasts, who suffered from high transfusional requirements and who did not respond to the administrations of B12 vitamin, folates, danazol, low dose cytarabine or recombinant human erythropoietin (rHuEPO). The patient was administered two cytokines: granulocyte colony stimulating factor (G-CSF) followed by rHuEPO. The patient remained transfusion free for more than 4 months until his death from causes not related to MDS or the therapy he received. It is the opinion of the authors that the initial G-CSF administration stimulated the early erythroid precursors, making them capable of finishing their maturation when rHuEPO was administered. We believe that this could be a useful therapeutic measure in the treatment of patients with MDS and high transfusional requirements.


Subject(s)
Anemia, Refractory/therapy , Erythrocyte Transfusion , Erythropoietin/therapeutic use , Granulocyte Colony-Stimulating Factor/therapeutic use , Fatal Outcome , Humans , Male , Middle Aged , Recombinant Proteins
2.
Rev Invest Clin ; 48(4): 281-7, 1996.
Article in Spanish | MEDLINE | ID: mdl-8966391

ABSTRACT

We studied 30 patients in order to evaluate the therapeutic efficacy and toxicity of alfa interferon associated with busulfan as maintenance treatment in de novo chronic granulocytic leukemia. Patients received 0.2 mg/kg of busulfan and reached complete hematological remission (CHR). Patients were then randomized in two groups: one to receive busulfan to be administered when the leukocyte count was above 15 x 10(9)/L, and another to receive subcutaneously 5 million IU of alpha-interferon three times per week (plus busulfan if the leukocyte count went above 15 x 10(9)/L). The duration of CHR was longer in the alfa-interferon group: 31 vs 16 months (p = 0.03) but no cytogenetic remissions were observed. Alfa interferon was well tolerated: no patient was excluded from the study due to toxicity.


Subject(s)
Antineoplastic Agents/therapeutic use , Busulfan/therapeutic use , Interferon-alpha/therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Adolescent , Adult , Female , Humans , Male , Middle Aged , Prospective Studies , Remission Induction
SELECTION OF CITATIONS
SEARCH DETAIL
...